Wednesday 28 October 2020

Vaccine could be ready by mid-October, says BioNTech CEO

NEW YORK, September 9, 2020

A Covid-19 vaccine being developed by the US-German pharmaceutical cooperation between Pfizer and BioNTech is “near perfect” and could be ready for approval by mid-October, said BioNTech CEO and co-founder Ugur Sahin in an interview with CNN's Frederik Pleitgen.
“It has an excellent profile and I consider this vaccine as a vaccine which is near perfect, and which has a near perfect profile,” he said.
The companies say they plan to provide 100 million doses of the vaccine (BNT162) by the end of the year and up to 1.3 billion in 2021.
Sahin told CNN he believes the approval for emergency use will be granted quickly by regulatory authorities. “Given that we have addressed the full package which is required for vaccine development including scientific studies, pre-clinical studies, safety tolerability testing and efficacy testing, there should not be too much time between emergency use authorisation and full approval,” he added. - TradeArabia News Service


More Health & Environment Stories

calendarCalendar of Events